Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus (131)I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

PURPOSE: SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133–tositumomab radioimmunotherapy) for previously untreated pati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Shadman, Mazyar, Li, Hongli, Rimsza, Lisa, Leonard, John P., Kaminski, Mark S., Braziel, Rita M., Spier, Catherine M., Gopal, Ajay K., Maloney, David G., Cheson, Bruce D., Dakhil, Shaker, LeBlanc, Michael, Smith, Sonali M., Fisher, Richard I., Friedberg, Jonathan W., Press, Oliver W.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2018
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553811/
https://ncbi.nlm.nih.gov/pubmed/29356608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.5083
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge